1. Home
  2. JFR vs ATTO Comparison

JFR vs ATTO Comparison

Compare JFR & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

N/A

Current Price

$7.05

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Attovia Therapeutics Inc. Common Stock

ATTO

Attovia Therapeutics Inc. Common Stock

N/A

Current Price

$15.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFR
ATTO
Founded
2004
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2004
2026

Fundamental Metrics

Financial Performance
Metric
JFR
ATTO
Price
$7.05
$15.13
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $43.20
AVG Volume (30 Days)
★ 745.2K
225.9K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 11.31%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.06
$12.94
52 Week High
$8.00
$28.00

Technical Indicators

Market Signals
Indicator
JFR
ATTO
Relative Strength Index (RSI) 36.91 44.83
Support Level N/A $13.52
Resistance Level $7.64 $17.10
Average True Range (ATR) 0.09 1.39
MACD -0.02 0.09
Stochastic Oscillator 2.86 28.75

Price Performance

Historical Comparison
JFR
ATTO

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests the majority of its managed assets in secured senior loans and unsecured senior loans, which unsecured senior Loans are generally, at the time of investment, investment grade quality.

About ATTO Attovia Therapeutics Inc. Common Stock

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

Share on Social Networks: